Is Moderna Stock Too Expensive in 2022?

Is Moderna Stock Too Expensive in 2022?
·4 min read

Moderna (NASDAQ: MRNA) stock has soared for the past two years thanks to its leadership in the coronavirus vaccine market. Then, they doubled down on their positions when Moderna commercialized its product and started to generate billions of dollars in revenue and profit. Considering this point, is Moderna stock too expensive?

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting